Ian Nessler

Bring your burning questions to this closing panel with all the seminar day’s presenters. With all ADC pharmacology topics up for discussion, hear the speakers delve into in-depth ADC MoA investigation, best utilize systems pharmacology modeling, and understand the transferable and non-transferable assumptions for bioconjugates with novel payloads and formats

• Examining unique delivery challenges encountered for solid tumor ADCs that may result in a binding-site barrier
• Investigating how mechanistic modeling, supported by quantitative experimental parameters, can inform on ideal drug design to overcome these challenges
• Focusing on how intentional protein-drug conjugate design can improve tumor penetration to expose the greatest number of tumor cells to a therapeutic concentration of payload

Whilst the path to the clinic is established for cytotoxic ADCs, in-depth knowledge of ADC MoA and tumor targeting behavior remains elusive, especially for ADCs with novel payloads and targeting moieties.

Attend this seminar day to leverage PD and systems pharmacology modeling to investigate ADC tumor targeting behavior, unlock transferable insights into non-cytotoxic ADC MoA, and assess applications of bioconjugates beyond oncology

Download the Full Event Guide for full details